11/11
07:00 am
aciu
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
Medium
Report
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
11/4
12:38 pm
aciu
AC Immune (NASDAQ:ACIU) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $8.00 price target on the stock.
Low
Report
AC Immune (NASDAQ:ACIU) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $8.00 price target on the stock.
11/4
07:00 am
aciu
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Medium
Report
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
10/28
07:00 am
aciu
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
Medium
Report
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
10/24
08:50 am
aciu
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
High
Report
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
10/3
02:37 pm
aciu
AC Immune (NASDAQ:ACIU) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
AC Immune (NASDAQ:ACIU) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/25
07:13 am
aciu
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine [Yahoo! Finance]
Low
Report
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine [Yahoo! Finance]
9/25
07:00 am
aciu
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
Medium
Report
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
9/11
07:13 am
aciu
AC Immune (NASDAQ:ACIU) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Low
Report
AC Immune (NASDAQ:ACIU) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
9/8
08:05 am
aciu
AC Immune (NASDAQ:ACIU) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $8.00 price target on the stock.
Medium
Report
AC Immune (NASDAQ:ACIU) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $8.00 price target on the stock.